Premium
Regulatory T cells are expanded by Teriparatide treatment in humans and mediate intermittent PTH ‐induced bone anabolism in mice
Author(s) -
Yu Mingcan,
D'Amelio Patrizia,
Tyagi Abdul Malik,
Vaccaro Chiara,
Li JauYi,
Hsu Emory,
Buondonno Ilaria,
Sassi Francesca,
Adams Jonathan,
Weitzmann M Neale,
DiPaolo Richard,
Pacifici Roberto
Publication year - 2018
Publication title -
embo reports
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 4.584
H-Index - 184
eISSN - 1469-3178
pISSN - 1469-221X
DOI - 10.15252/embr.201744421
Subject(s) - teriparatide , anabolism , endocrinology , medicine , microbiology and biotechnology , chemistry , biology , osteoporosis , bone mineral
Teriparatide is a bone anabolic treatment for osteoporosis, modeled in animals by intermittent PTH ( iPTH ) administration, but the cellular and molecular mechanisms of action of iPTH are largely unknown. Here, we show that Teriparatide and iPTH cause a ~two‐threefold increase in the number of regulatory T cells (Tregs) in humans and mice. Attesting in vivo relevance, blockade of the Treg increase in mice prevents the increase in bone formation and trabecular bone volume and structure induced by iPTH . Therefore, increasing the number of Tregs is a pivotal mechanism by which iPTH exerts its bone anabolic activity. Increasing Tregs pharmacologically may represent a novel bone anabolic therapy, while iPTH ‐induced Treg increase may find applications in inflammatory conditions and transplant medicine.